ACPE UAN #: 0233-0000-20-008-H04-P
Release Date: April 23, 2020
Expiration Date: April 23, 2022
Activity Type: Knowledge-based
Contact Hours: 1.0 contact hours
Activity Fee: Member: Free Non-Member: $30
Target Audience: Pharmacists who practice in managed care settings.
Despite a lack of regulatory and legal clarity, significant numbers of patients in Medicare, Medicaid, CHIP, and commercial plans currently use medical cannabis. Clinicians and payers need to be aware of this fact and familiarize themselves with cannabinoids, regardless of whether they are FDA approved. Federal restrictions have limited investigational access to authorized cannabis crops, which directly affects the ability of stakeholders to gather any quality evidence either supporting or undermining its use. Questions remain over what supportive data is available for cannabis use, where can it be found, and for which disease states? While no states currently require health plan coverage of medical cannabis, reimbursement is being tested by payers in other industries, such as workers’ compensation., Their experience can provide a valuable template for health plans and others to either adopt or avoid as pressure to cover medical cannabis increases.
This interactive session will provide a basic introduction to cannabinoids and the endocannabinoid system. It also will explore the impact of legislative/regulatory affairs on research, provide reimbursement examples, and examine strategies that guide cannabis clinicians in their treatment of patients. The session will also feature case studies that address many of the questions clinicians have regarding clinically significant outcomes.
At the completion of this activity, participants should be able to:
- Describe cannabis terminology, the endocannabinoid system (ECS), and the mechanism of action of various cannabinoids on the ECS
- Summarize federal and state legislative and regulatory issues and their effect on the quality and availability of clinical cannabis research
- Explain the different methods of payment and/or reimbursement and how they relate to payers
- Identify the methodical strategies used by clinicians to optimize treatment, minimize risks, and improve lives using cannabinoids
Schedule of Educational Activity
This activity consists of an audio recording, pre-test assessment questions (not required to pass to continue), post-test questions (required to pass with a score of 70% or higher) and a specific activity evaluation.
Participants should claim continuing pharmacy education (CPE) credit for this home study activity only if they have not claimed credit for the live webinar activity presented at AMCP eLearning Days.
CPE credit will be processed through the AMCP Learn portal and reported directly to CPE Monitor. Please allow 72 hours for processing and posting in your NABP account.
To receive credit for an online activity you must:
- Review the full content of the activity.
- Successfully complete the post-test (required to pass with a score of 70% or higher, it may be taken a maximum of three times).
- Complete a specific activity evaluation.
System Technical Requirements/Viewing Requirements: System Requirements Courses and learning activities are delivered via your Web browser and Acrobat PDF. For all activities, you should have a basic comfort level using a computer and navigating web sites. View the minimum technical and system requirements for continuing education online learning activities.
As an accredited provider, AMCP strictly adheres to the ACPE Standards for Commercial Support and other relevant guidelines and standards to ensure the independence of continuing pharmacy education (CPE) activities. It is AMCP’s intent that all CPE activities be independent, objective, balanced, evidence-based and free of any commercial bias.
Brittany Henry, Assistant Director, Educational Programs , AMCP, Alexandria, Virginia
|Activity Number||Credit Amount||Accreditation Period|
|ACPE UAN #0233-0000-20-008-H04-P||1 Contact Hour||April 23, 2020 - April 23, 2023|